Omrix, as you know are conducting a trial for a fibrin pad, which at a selling point of $500 will enter the market 2008 with US unit sales of 20,853 capturing 20% of the market share (according to the 2005 un-updated report at Omrix website, link below). This is expected to grow to a peak of 70% of the market by 2013.
While EMS and military use is apparently not the main focus for sales, it appears the US market is the main target further aimed at "less price sensitive" surgeons.
READ MORE AT http://medicalhemostat.blogspot.com/
